Mito Health

Most people don’t need more tests. They need to know which tests actually matter. That’s what we built the new Mito to solve with evidence-based recommendations and transparent pricing starting from $2.50. 🚀 We’re live on Product Hunt today. If you’d like to support our mission, we’d be incredibly grateful for your upvote. producthunt.com/posts/mito-hea…

Let’s lead the industry with real cost plus testing and labs. 👀

Retatrutide: 30.3% weight loss at 2 years. Triple agonist. Phase 3. We're entering an era where the molecule isn't the question... the right protocol, the right person, the right biomarkers to track is. And everyone in health, outside of the AI-sphere in going crazy. The mechanism story is bigger, and almost nobody will explain it today. TRIUMPH-1 headlines: → 70 lbs (31.7kg) average weight loss on 12mg at 80 weeks (1.5 years) → 45% of high-dose patients hit ≥30% body weight reduction (this is bariatric surgery territory) → 65% dropped below the obesity BMI threshold entirely → In the BMI ≥35 extension cohort, weight loss was still trending down at 104 weeks → even 4mg delivered ~19% loss with discontinuation rates below placebo → significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP → no cardiac or liver signals Everyone will post the numbers today. Here's what most of them won't explain. The reason retatrutide keeps working when other GLP-1s slow down is the glucagon receptor. 1. Semaglutide is GLP-1 alone. 2. Tirzepatide adds GIP. Neither touches glucagon (a hormone produced by the pancreas that raises blood sugar levels by prompting the liver to release stored glucose). Both suppress appetite and improve insulin sensitivity: but neither directly drives energy expenditure the way glucagon does. Glucagon does three things that appetite suppression alone can't: 1. Tells the liver to burn fat directly 2. Raises resting metabolic rate 3. Suppresses new fat creation from carbohydrates That's why semaglutide and tirzepatide trials tend to plateau around 60–72 weeks. The body adapts. Metabolism slows. The drug becomes a brake on intake, not an accelerator on output. Retatrutide (a triple-agonist = a type of medication that simultaneously binds to and activates three different hormone receptors to regulate appetite, blood sugar, and metabolism) It keeps the furnace running on the output side while suppressing the input side. That's the mechanistic reason the extension data was still trending down at 104 weeks while everyone else's curves flatten. The likely downstream consequence — supported but not yet head-to-head proven: more visceral fat loss, better lipid improvements, more durable metabolic remission. The Phase 2 visceral fat data already pointed this direction. The bigger implication for our industry: "GLP-1" was never really a category. It was a placeholder until we had multi-receptor molecules that target the metabolic system as a system. Today's results make that real. Full press release in comments.

Today at @usemitohealth , you can order + interpret on a n=1 personalized level: 1. All types of advanced blood panels 2. Galleri GRAIL Multi Cancer Early Detection screening (up to 50 cancers) 3. Prenuvo MRI Scans 4. Gut Microbiome testing with Tiny Health (shotgun sequencing) 5. DEXA body composition scans 6. DNA low-pass sequencing for Polygenic Risk Scores (PRS) - NEW Bullish on where we're headed towards in the broader scheme of things - Precision healthcare, all the way from diagnostics, prevention, and treatment.

Longevity is not just about living longer. It’s about spotting what’s changing in your health early enough to do something about it. Better metabolic, hormonal, and cardiovascular data should be part of everyday preventive care.

Really strong positioning, Mito Health turning generic lab panels into goal-specific, AI-designed biomarker stacks is seriously well done. I operate heavily in crypto and AI circles and this hits a real gap with high-performance founders, biohackers, and quantified-self operators who don’t want 100 irrelevant markers, they want signal tied to a specific objective. The overlap is strong with optimization-driven communities tracking longevity, hormones, performance, and recovery with precision. I’ve got visibility options to get this trending on the right timelines and we know how to position AI-native diagnostics like this so they become the main conversation around personalized health infrastructure for weeks, shoot me a DM.

@StockTrader_Max There are so many companies offering labs today. What $hims is offering isn’t anything earth shattering. I used @usemitohealth for my labs before $hims and it was cheaper and better

@ctranbtw Thank you for the shoutout 🙏

See you in Jan 2026. Looking forward to an evening of curated conversations on longevity, health, and more. Limited slots. RSVP here: luma.com/uh8yeqkh

@kobyjconrad 100%. My cofounder lost his dad early to cancer, and it’s a big reason why we started @usemitohealth. MRI + GRAIL + comprehensive bloodwork all in one place, to help you pick up early signs even before your doctor does

At Mito Health, we test for 100+ biomarkers, provide MD-guided insights and a personalized health plan to optimize your health now and protect it for the long run. x.com/usemitohealth/… Learn more: mitohealth.com/blog/red-light…

It offers a noninvasive way to nourish aging retinal cells. Keep it simple. Use the right tool at the right dose, and pair it with daylight, breaks for your eyes, and cardio-friendly habits. That is how a small beam of light can contribute to a longer, clearer healthspan.

Red light therapy is usually meant for sleep but did you know it could play a role in your vision too? The same gentle wavelengths people use for wind-down routines can interact with the most energy-hungry tissue in the body, the retina. A thread. 🧵